Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal insulin for smoking behavior biomarkers
NCT03811951Phase 2Terminated
- Sponsor
- University of Illinois Chicago
- Start
- Sep 2018
- Primary completion
- Sep 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of regular human insulin in Tobacco Use Disorder (TUD) (2 arms), sponsored by University of Illinois Chicago. Primary endpoint: Go/No-Go Accuracy. Started Sep 2018; status: terminated.
02
Drugs
regular human insulin
03
Conditions
Tobacco Use Disorder (TUD)
Beyond the preview
Go deeper on NCT03811951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03811951.